株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

心臓バイオマーカー:技術・世界市場

Cardiac Biomarkers: Technologies and Global Markets

発行 BCC Research 商品コード 297159
出版日 ページ情報 英文 292 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.74円で換算しております。
Back to Top
心臓バイオマーカー:技術・世界市場 Cardiac Biomarkers: Technologies and Global Markets
出版日: 2018年06月22日 ページ情報: 英文 292 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の心臓バイオマーカー市場規模は2017年の63億米ドルから、2022年までに99億米ドルへ拡大すると予測され、この間のCAGR (年間複合成長率) は9.5%が見込まれています。

当レポートでは、世界の心臓バイオマーカー市場および関連技術について調査し、実績・推計・CAGR予測を含む世界市場の動向、分類別による疾病の分析、心臓バイオマーカーの背景・臨床価値、特許動向、および政府規制などをまとめています。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 心血管疾患・心血管疾患のフラン

  • 心血管疾患の概要
  • 疾病管理
  • 世界の心血管疾患の負担

第4章 心臓バイオマーカーのイントロダクション

  • バイオマーカーの種類
  • 心不全の予防、評価および管理におけるバイオマーカーの役割
  • バイオマーカーの発見と承認
  • バイオマーカーの発見のオミクス技術
  • 心臓バイオマーカーを開発する際の検討ジコウ
  • バイオマーカー異常値の定義
  • バイオマーカー精度のROC (受信者動作特性) 曲線分析

第5章 主な心臓バイオマーカーのレビュー

  • 心臓バイオマーカーの基準
  • トロポニン複合体
  • Pro-BNP および/またはNT-proBNP
  • クレアチンキナーゼテスト
  • ミオグロビン (Mb)
  • C反応性蛋白
  • その他の主な心臓バイオマーカー
  • 新興の心臓バイオマーカー

第6章 世界の心臓バイオマーカー市場分析

  • イントロダクション
  • 世界の心臓バイオマーカー市場:心臓バイオマーカータイプ別
  • 地域概要
  • 心臓バイオマーカー市場シェア:地域別

第7章 心臓バイオマーカーの規制・法的要件

  • 北米
  • 欧州
  • 日本
  • 中国
  • インド
  • 韓国
  • ブラジル
  • アルゼンチン
  • メキシコ

第8章 心臓バイオマーカーの特許レビュー・新規開発

  • イントロダクション
  • 心臓バイオマーカー特許:地域・国別

第9章 企業プロファイル

  • ABBOTT LABORATORIES
  • ACS BIOMARKER BV
  • BECKMAN COULTER (PART OF DANAHER)
  • BG MEDICINE INC.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES INC.
  • CARDIOGENICS
  • CAVADIS
  • CRITICAL DIAGNOSTICS
  • CRUINN MEDICAL LTD.
  • HEALTH-CHEM DIAGNOSTICS
  • LIFE DIAGNOSTICS INC.
  • LIFESIGN
  • LSI MEDIENCE CORP.
  • MERIDIAN LIFE SCIENCE INC.
  • METANOMICS HEALTH GMBH
  • MIRNEXT
  • ORTHO-CLINICAL DIAGNOSTICS INC.
  • PTS DIAGNOSTICS
  • RADIOMETER MEDICAL APS
  • RANDOX LABORATORIES LTD.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE (FORMERLY HOFFMANN-LA ROCHE LTD.)
  • 三洋化成工業
  • SIEMENS AG
  • SINGULEX INC.
  • SPECTRAL MEDICAL, INC.
  • THERMO FISHER SCIENTIFIC
  • TOSOH BIOSCIENCE INC.
  • TRINITY BIOTECH PLC
  • ZENOSENSE INC.

第10章 付録A

第11章 付録B

第12章 付録C

図表

List of Tables

  • Summary Table A: Global Cardiac Biomarker Market, by Biomarker Type, Through 2022
  • Summary Table B: Global Cardiac Biomarker Market Share, by Region, 2017
    • Table 1: Standard Angina Pectoris Classification
    • Table 2: Top 20 Leading Causes of Death, 2015
    • Table 3: Estimated Deaths Due to Noncommunicable Diseases, by Sex and Disease, 2015
    • Table 4: Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2015
    • Table 5: Global Health Estimates, by Sex and WHO Region, 2015
    • Table 6: Estimated Deaths Due to Cardiovascular Disease, by Sex and Disease, 2030
    • Table 7: Estimated Deaths Due to Cardiovascular Disease, by Sex and WHO Region, 2030
    • Table 8: Economic Burden of NCDs in India, 2012-2030
    • Table 9: Summary of Heart Failure Biomarkers
    • Table 10: Cardiac Biomarkers of Myocyte Stretch
    • Table 11: Cardiac Biomarkers of Myocyte Injury
    • Table 12: Cardiac Biomarkers of Oxidative Stress
    • Table 13: Cardiac Biomarkers of Neurohormonal Activation
    • Table 14: Prognostic and Diagnostic Values and Analytical Performance of Inflammatory Markers in Coronary Artery Disease
    • Table 15: Cardiac Biomarkers of Inflammation and Atherogenesis
    • Table 16: Cardiac Biomarkers of Renal Dysfunction
    • Table 17: Soluble Cell Adhesion Molecules
    • Table 18: Cardiac Biomarkers of Thrombosis
    • Table 19: Cardiac Biomarkers of Metabolic/Lipid Dysregulation
    • Table 20: Cardiac Biomarkers of Brain Damage
    • Table 21: Techniques Available for Biomarker Development
    • Table 22: Desirable Features of Cardiac Biomarkers
    • Table 23: Common Cardiac Biomarkers
    • Table 24: Contemporary Cardiac Troponin I and T Assay Analytical Characteristics as Designated by the Manufacturer
    • Table 25: High Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
    • Table 26: Point-of-Care Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
    • Table 27: BNP, NT-proBNP and MR-proANP Assays: Analytical Characteristics Designated by Manufacturer
    • Table 28: Profile of Biomarker Myoglobin
    • Table 29: Profile of Biomarker ST2
    • Table 30: Global Cardiac Biomarker Market, Through 2022
    • Table 31: Global Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 32: Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
    • Table 33: Global Cardiac Biomarker Market Share, by Region, 2017
    • Table 34: Global Cardiac Biomarker Market, by Region, 2017
    • Table 35: Global Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 36: North American Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 37: North American Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 38: Projections of Crude CVD Prevalence in the United States, 2010-2030
    • Table 39: North American Cardiac Biomarker Market Share, by Country, 2017
    • Table 40: United States Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 41: Canadian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 42: European Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 43: European Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 44: European Cardiac Biomarker Market Share, by Country, 2017
    • Table 45: French Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 46: German Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 47: Italian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 48: Spanish Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 49: United Kingdom Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 50: Benelux Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 51: Scandinavian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 52: Rest of Europe Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 53: Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 54: Asia-Pacific Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 55: Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017
    • Table 56: Japanese Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 57: Chinese Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 58: Indian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 59: South Korean Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 60: Rest of Asia-Pacific Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 61: Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 62: Central and Latin American Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 63: Central and Latin American Cardiac Biomarker Market Share, by Country, 2017
    • Table 64: Argentinian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 65: Brazilian Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 66: Chilean Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 67: Mexican Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 68: Rest of Central and Latin American Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 69: Middle East and African Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 70: Middle East and African Cardiac Biomarker Market, by Instrument Category, Through 2022
    • Table 71: Middle East and African Cardiac Biomarker Market Share, by Region, 2017
    • Table 72: Middle Eastern Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 73: African Cardiac Biomarker Market, by Biomarker Type, Through 2022
    • Table 74: Global Cardiac Biomarker Market Share, by Company, 2017
    • Table 75: North American Cardiac Biomarker Market Share, by Company, 2017
    • Table 76: European Cardiac Biomarker Market Share, by Company, 2017
    • Table 77: Asia-Pacific Cardiac Biomarker Market Share, by Company, 2017
    • Table 78: Latin and Central American Cardiac Biomarker Market Share, by Company, 2017
    • Table 79: Middle East and African Cardiac Biomarker Market Share, by Company, 2017
    • Table 80: ICD-9 and ICD 10 CM Diagnosis Codes Commonly Used to Report Cardiac Conditions
    • Table 81: Clinical Diagnostic Laboratory Fee Schedule, 2018
    • Table 82: Comparison of Pharmaceutical Affair Law and Japanese Medical Device Nomenclature and Related Codes with the EU MDD
    • Table 83: Number of Healthcare Institutions According to Ownership in China, 2010
    • Table 84: Total Number of Hospitals by Ranking in China, 2010
    • Table 85: Overview of Healthcare in India
    • Table 86: Recent Canadian Patent Publications Relating to Cardiac Biomarkers
    • Table 87: Recent Chinese Patent Publications Relating to Cardiac Biomarkers
    • Table 88: Recent European Patent Publications Relating to Cardiac Biomarkers
    • Table 89: Recent Eastern European Patent Publications Relating to Cardiac Biomarkers
    • Table 90: Recent U.S. Patent Publications Relating to Cardiac Biomarkers
    • Table 91: Recent Asia-Pacific Patent Publications Relating to Cardiac Biomarkers
    • Table 92: Recent Global Patent Publications Relating to Cardiac Biomarkers
    • Table 93: Abbott Laboratories' Revenue, by Business Segment, 2014-2016
    • Table 94: Danaher's Revenue, by Business Segment, 2014-2016
    • Table 95: BioMerieux S.A.'s Sales, by Application, 2015 to 2016
    • Table 96: Bio-Rad Laboratories Inc.'s Revenue, by Business Segment, 2014-2016
    • Table 97: Roche Group's Revenue, by Business Segment, 2014-2016
    • Table 98: Roche Group's Revenue, by Diagnostic Segment, 2014-2016
    • Table 99: Siemens AG Cardiovascular Assay Menu
    • Table 100: Thermo Fisher Scientific's Revenue, by Business Segment, 2014-2016
    • Table 101: Thermo Fisher Scientific's Results of Operations, by Region, 2014-2016
    • Table 102: Company Addresses and Contact Details
    • Table 103: Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers
    • Table 104: Commonly Used Acronyms Associated with Cardiac Biomarkers

List of Figures

  • Summary Figure A: Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
  • Summary Figure B: Global Cardiac Biomarker Market Share, by Region, 2017
    • Figure 1: Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2015
    • Figure 2: Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2015
    • Figure 3: Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age, 2015
    • Figure 4: Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2015
    • Figure 5: Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2030
    • Figure 6: Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2030
    • Figure 7: Global Distribution of Female Deaths Caused, by Cardiovascular Disease, by Age, 2030
    • Figure 8: Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2030
    • Figure 9: Projected Total Costs of Cardiovascular Disease in The United States, 2015-2030
    • Figure 10: Classes of Biomarkers Contributing to the HF Biomarker Profile
    • Figure 11: Possible Roles of C-Reactive Protein in the Pathogenesis of Metabolic Syndrome and Cardiovascular Disorders
    • Figure 12: Biomarker Use in Heart Failure Trials
    • Figure 13: Approaches to Defining Abnormal Biomarker Values
    • Figure 14: Receiver Operating Characteristic Curve in Different Cardiac Biomarkers
    • Figure 15: Interpreting Elevated Levels of Cardiac Troponin
    • Figure 16: Comparison of 19 Cardiac Troponin Assays
    • Figure 17: Schematic Diagram of the Synthesis of NT-proBNP and BNP from the Pre-proBNP Protein by Cardiomyocytes
    • Figure 18: Interpretation of NT-proBNP Values as a Predictor of Heart Failure
    • Figure 19: Global Cardiac Biomarker Market Share, by Biomarker Type, 2017
    • Figure 20: Global Cardiac Biomarker Market Share, by Region, 2017
    • Figure 21: North American Cardiac Biomarker Market, by Biomarker Type, 2017
    • Figure 22: North American Cardiac Biomarker Market Share, by Country, 2017
    • Figure 23: United States Cardiac Biomarker Market, by Biomarker Type, 2017
    • Figure 24: European Cardiac Biomarker Market, by Biomarker Type, 2017
    • Figure 25: European Cardiac Biomarker Market Share, by Country, 2017
    • Figure 26: Asia-Pacific Cardiac Biomarker Market, by Biomarker, 2017
    • Figure 27: Asia-Pacific Cardiac Biomarker Market Share, by Country, 2017
    • Figure 28: Central and Latin American Cardiac Biomarker Market, by Biomarker Type, 2017
    • Figure 29: Central and Latin American Cardiac Biomarker Market Share, by Country, 2017
    • Figure 30: Middle East and African Cardiac Biomarker Market, by Biomarker Type, 2017
    • Figure 31: Middle East and African Cardiac Biomarker Market Share, by Region, 2017
    • Figure 32: Private Health Insurance Coverage for U.S. Residents under 65, 2007-2011
    • Figure 33: Illustration of Medicare Payment Process
    • Figure 34: French Pricing and Reimbursement Process for Medical Devices
    • Figure 35: Market Access Pathway for Inpatient Medical Devices in Italy
    • Figure 36: Market Access Pathway for Outpatient Medical Devices in Italy
    • Figure 37: The Chinese Healthcare System
目次
Product Code: BIO128C

Report Highlights

The global market for cardiac biomarker will grow from $6.3 billion in 2017 to $9.9 billion by 2022, at a compound annual growth rate (CAGR) of 9.5% for the period of 2017-2022

Report Scope

The principal objectives of this report are to:

  • Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
  • Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications.
  • Discover feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
  • Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
  • Present market figures for the current value of the cardiac marker testing market, projections and growth rates. These are taken from the most recently available from the global diagnostics industry.

By purchasing this study, the reader will gain:

  • An improved understanding of the current state and future of the most exciting cardiac marker diagnostic testing market segments.
  • The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses.
  • A leading perspective of recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets.
  • Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment.

This analysis covers the following categories of the cardiac diagnostic testing segments:

  • AMI.
  • Heart failure.
  • Brain natriuretic peptide (BNP).
  • Myoglobin.
  • Homocysteine (Hcy).
  • C-reactive protein (CRP).
  • Pulmonary embolism (PE) D-dimer test.
  • Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
  • Stroke.
  • Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
  • Albumin.
  • Cardiac markers used in clinical decisions.
  • Cardiac markers in renal failure.
  • Troponins in non-ischemic heart disease.
  • Cardiac panels.
  • POC cardiac markers.

Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study:

  • Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
  • Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
  • Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
  • Provides current and forecasted market shares by company.
  • Discusses profit and business opportunities by diagnostic testing segment.
  • Provides strategic recommendations for near-term business opportunities.
  • Assesses current commercial uses of the cardiac marker diagnostic testing market.

Report Includes:

  • 64 data table and 40 additional tables
  • An overview of the global market for cardiac biomarkers and related technologies
  • Analyses of global market trends, with data from 2016 to 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Classification of cardiac biomarkers by cerebrovascular, congestive, coronary, hypertensive, and peripheral arterial disease
  • Background and clinical values of cardiac biomarkers, including B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI)/troponin T (cTnT)
  • Examination of the technology regarding diagnostic methods, instrumentation, newly issued patents, and new patent applications
  • Coverage of clinical guidelines and government regulations
  • Comprehensive company profiles of major Players in the Market including Abbott Laboratories, Biomerieux S.A., Bio-Rad Laboratories Inc, Life Diagnostics Inc., Meridian Life Science Inc. Randox Laboratories Ltd., Roche, Sanyo Chemical Industries Ltd., Siemens Ag, and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 - Introduction

  • Scope of the Report
  • Methodology and Information Sources
    • Primary Data and Information Gathering
    • Secondary Data and Information Gathering
    • Market Share Analysis and Market Forecast Prediction
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2 - Summary and Highlights

Chapter 3 - Cardiovascular Disease and Burden of Cardiovascular Disease

  • Overview of Cardiovascular Disease
    • Coronary Artery Disease
    • Atherosclerosis
    • Angina (Angina Pectoris)
    • Acute Myocardial Infarction
  • Disease Management
    • Medical Management
    • Lifestyle Changes
    • Diet Modification
    • Smoking Cessation
    • Pharmaceuticals
    • Anticoagulants and Antiplatelet Drugs
    • Lipid-Lowering Drugs
    • Anti-Hypertensive Drugs
    • Nitroglycerin Preparations
    • Surgical Intervention
  • The Global Burden of Cardiovascular Disease
    • Global Burden of Cardiovascular Disease, 2015
    • 2030 Global Burden of Cardiovascular Disease
    • The Global Economic Burden of Cardiovascular Disease

Chapter 4 - Introduction to Cardiac Biomarkers

  • Types of Biomarkers
    • Antecedent Biomarker Tests
    • Screening Biomarker Tests
    • Diagnostic Biomarker Tests
    • Staging Biomarkers
    • Prognostic Biomarker Tests
  • Role of Biomarkers in the Prevention, Assessment and Management of Heart Failure
    • Myocardial Stress/Injury
    • Neurohormonal Activation
    • Remodeling
    • Comorbidities
    • Other Biomarkers of Cardiac Activity
    • Their Role of Biomarkers in Heart Failure Clinical Trials
  • Biomarker Discovery and Validation
    • Biomarker Candidate Screening
    • Biomarker Candidate Validation
  • Omic Technologies for Biomarker Discovery
    • Genomics
    • Proteomics
    • Metabolomics
    • Lipidomics
  • Considerations When Developing a Cardiac Biomarker
  • Defining Abnormal Biomarker Values
    • Reference Limits
    • Discrimination Limits
    • Threshold Defining Risk
  • Receiver Operating Characteristic Curve Analysis of Biomarker Accuracy

Chapter 5 - Review of Key Individual Cardiac Biomarkers

  • Gold Standard of Cardiac Biomarkers
  • Troponin Complex
    • Troponin C
    • Troponin T
    • Troponin I
    • Troponin as the Preferred Biomarker
    • High Sensitivity Troponin Assays
    • Emergence of Point-of-Care Troponin Testing
  • Pro-BNP and/or NT-proBNP
  • Creatine Kinase Test
  • Myoglobin (Mb)
  • C-Reactive Protein
  • Other Key Cardiac Biomarkers
    • Copeptin
    • D-dimer
    • Galectin-3
    • Fatty Acid Binding Proteins
    • ST2
  • Emerging Cardiac Biomarkers
    • Choline
    • Ischemia-Modified Albumin
    • Myeloperoxidase
    • S100-beta
    • Recent Technological Advances and Key Developments in Cardiac Biomarker Measurement

Chapter 6 - Global Cardiac Biomarker Market Analysis

  • Introduction
  • Global Cardiac Biomarker Market by Cardiac Biomarker Type
  • Regional Overview
    • North American Cardiac Biomarker Market Analysis
      • Selected Drivers of the North American Cardiac Biomarker Market
      • Selected Restraints of the North American Cardiac Biomarker Market
      • North American Cardiac Biomarker Market, by Country
    • European Cardiac Biomarker Market Analysis
      • Selected Drivers of the European Cardiac Biomarker Market
      • Selected Restraints of the European Cardiac Biomarker Market
      • European Cardiac Biomarker Market, by Country
    • Asia-Pacific Cardiac Biomarker Market Analysis
      • Selected Drivers of the Asia-Pacific Cardiac Biomarker Market
      • Selected Restraints of the Asia-Pacific Cardiac Biomarker Market
      • Asia-Pacific Cardiac Biomarker Market by Country
    • Central and Latin American Cardiac Biomarker Market Analysis
      • Selected Drivers of the Central and Latin American Cardiac Biomarker Market
      • Selected Restraints of the Central and Latin American Cardiac Biomarker Market
      • Central and Latin American Cardiac Biomarker Market by Country
    • Middle East and African Cardiac Biomarker Market Analysis
      • Selected Drivers of the Middle East and African Cardiac Biomarker Market
      • Selected Restraints of the Middle East and African Cardiac Biomarker Market
      • Middle East and African Cardiac Biomarker Market by Region
  • Cardiac Biomarker Market Shares by Geographic Region
    • Global Market Share Analysis

Chapter 7 - Regulatory and Legislative Requirements for Cardiac Biomarkers

  • North America
    • United States
    • Recent Developments
    • Canada
  • Europe
    • (General) Medical Device Directive, MDD (93/42/EEC)
    • Active Implantable Medical Device Directive, AIMDD (90/383/EEC)
    • In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
    • Proposed Changes to the Medical Device Directive, MDD (93/42/EEC)
    • Notified Bodies
    • German Reimbursement Structure and Schedules for Diagnostic Procedures
    • French Reimbursement Structure and Schedules for Diagnostic Procedures
    • Italian Reimbursement Structure and Schedules for Diagnostic Procedures
  • Japan
    • Marketing Authorization System
  • China
    • Overview of the Healthcare System
    • Healthcare Reforms
    • Healthcare Institutions
  • India
    • Overview of the Healthcare System
    • Hospital Resources
    • Population Statistics
  • South Korea
  • Brazil
    • Background
    • Regulatory and Legislative Requirements
    • Market Entry and Reimbursement of Medical Devices
  • Argentina
    • Background
  • Mexico
    • Legislation and Regulations Governing Medical Devices in Mexico
    • Health Insurance Structure

Chapter 8 - Patent Review and New Developments for Cardiac Biomarkers

  • Introduction
  • Cardiac Biomarker Patents by Region and Country

Chapter 9 - Company Profiles

  • ABBOTT LABORATORIES
  • ACS BIOMARKER BV
  • BECKMAN COULTER (PART OF DANAHER)
  • BG MEDICINE INC.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES INC.
  • CARDIOGENICS
  • CAVADIS
  • CRITICAL DIAGNOSTICS
  • CRUINN MEDICAL LTD.
  • HEALTH-CHEM DIAGNOSTICS
  • LIFE DIAGNOSTICS INC.
  • LIFESIGN
  • LSI MEDIENCE CORP.
  • MERIDIAN LIFE SCIENCE INC.
  • METANOMICS HEALTH GMBH
  • MIRNEXT
  • ORTHO-CLINICAL DIAGNOSTICS INC.
  • PTS DIAGNOSTICS
  • RADIOMETER MEDICAL APS
  • RANDOX LABORATORIES LTD.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE (FORMERLY HOFFMANN-LA ROCHE LTD.)
  • SANYO CHEMICAL INDUSTRIES LTD.
  • SIEMENS AG
  • SINGULEX INC.
  • SPECTRAL MEDICAL, INC.
  • THERMO FISHER SCIENTIFIC
  • TOSOH BIOSCIENCE INC.
  • TRINITY BIOTECH PLC
  • ZENOSENSE INC.

Chapter 10 - Appendix A: Company Addresses and Contact Details

  • Company Addresses and Contact Details

Chapter 11 - Appendix B: Government Regulatory Agencies and Professional Organizations

  • Government Regulatory Agencies and Professional Organizations

Chapter 12 - Appendix C: Commonly Used Acronyms Associated with Cardiac Biomarkers

Back to Top